The effect of GNRHA therapy initiation age on final height in girls with central precocious puberty

Agah Akın; Uğurlu Aylin Kılınc; Esra Doger; Mahmut Camurdan; Aysun Bideci

doi:10.1530/endoabs.110.P961

JOINT3584

Introduction: Precocious puberty is defined as puberty onset before 8 years in girls and 9 years in boys. Elevated estradiol accelerates growth but leads to premature epiphyseal closure, potentially resulting in short final height. In central precocious puberty (CPP), gonadotropin-releasing hormone agonists (GnRHa) mitigate psychosocial effects—such as early menarche—and improve final height. However, the effect of hormone initiation time on final height is controversial in the literature.

Aim: This study aims to determine the effect of GnRHa treatment initiation age on final height. We are analyzing CPP patients treated in our clinic from 2000 to 2024. Of the targeted 300 patients, 150 girls have been evaluated. This interim report presents our findings.

Methods: Patients were categorized into four groups based on treatment initiation age (Group 1: ≤7.99 years, n = 30; Group 2: 8–8.99 years, n = 55; Group 3: 9–9.99 years, n = 52; Group 4: ≥10 years, n = 13). Parameters were compared using one-way ANOVA and Bonferroni post-hoc tests.

Results:

Conclusion: Earlier treatment led to significantly greater final height and superior FH SDS and FH SDS–MPH SDS values. These findings emphasize the importance of early diagnosis and intervention. Once finalized, our study will contribute valuable data to the literature.

Table Baseline Characteristics and Final Heights of the Four Groups.
	Group 1 (n = 30)	Group 2 (n = 55)	Group 3 (n = 52)	Group 4 (n = 13)	All (n = 150)	P values
Age (years)	7.07±0.63	8.42±0.29	9.43±0.29	10.37±0.38	8.67±1.07	<0.001
HSDS	1.13±1.02	0.92±1.05	0.95±0.90	0.18±1.17	0.91±1.02	0.043
BMI SDS	0.89±1.03	0.86±0.86	0.79±0.79	0.53±1.04	0.81±0.89	0.644
MPH SDS	-0.81±0.95	-0.70±0.96	-0.67±0.84	-0.90±0.91	-0.73±0.91	0.810
BA (years)	8.58±1.23	10.01±0.87	11.05±0.79	11.52±0.62	10.21±1.33	<0.001
PFH SDS	-1.08±1.03	-1.34±0.82	-1.02±0.98	-1.31±1.13	-1.17±0.95	0.321
FH (cm)	162.08±6.44	160.18±5.84	159.61±4.83	156.42±5.15	160.04±5.71	0.023Φ
FH SDS	-0.18±1.10	-0.50±1.00	-0.59±0.82	-1.14±0.88	-0.52±0.97	0.024Ψ
FH SDS – MPH SDS*	0.63±0.86	0.20±0.81	0.07±0.77	-0.23±0.51	0.20±0.82	0.003♣
Values are presented as mean ± standard deviation. HSDS: height standard deviation score, BMI: body mass index, SDS: standard deviation score, MPH: mid-parental height, BA: bone age, PFH: predicted final height, FH: final height This parameter indicates the difference between the FH SDS and the MPH SDS. Φ Group 1 vs. Group 4* showed a significant difference in final height. ΨGroup 1 vs. Group 4 showed a significant difference in final height. ♣ Significant differences were found for Group 1 vs. Group 3 and Group 1 vs. Group 4.

Keywords: GnRH analogue, Precocious puberty, Final height.

Endocrine Abstracts

P961